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Aims Postural tachycardia syndrome (POTS), a common and debilitating cardiovascular disorder, is characterized by an ex-
aggerated heart rate increase during orthostasis and a wide spectrum of adrenergic-related symptoms. To determine
the aetiology of POTS, we examined a possible pathophysiological role for autoantibodies against a1-adrenergic
(a1AR) and b1/2-adrenergic receptors (b1/2AR).
Methods
and results
Immunoglobulin G (IgG) derived from 17 POTS patients, 7 with recurrent vasovagal syncope (VVS), and 11 normal
controls was analysed for its ability to modulate activity and ligand responsiveness of a1AR and b1/2AR in transfected
cells and to alter contractility of isolated rat cremaster arterioles in vitro. Immunoglobulin G activation of a1AR and b1/
2AR was significantly higher in POTS compared with VVS and controls in cell-based assays. Eight, 11, and 12 of the 17
POTS patients possessed autoantibodies that activateda1AR, b1AR andb2AR, respectively. Pharmacological blockade
suppressed IgG-induced activation of a1AR and b1/2AR. Eight of 17 POTS IgG decreased the a1AR responsiveness to
phenylephrine and 13 of 17 POTS IgG increased the b1AR responsiveness to isoproterenol irrespective of their ability
to directly activate their receptors. Postural tachycardia syndrome IgG contracted rat cremaster arterioles, which was
reversed bya1AR blockade. The upright heart rate correlated with IgG-mediated b1AR and a1AR activity but not with
b2AR activity.
Conclusion These data confirm a strong relationship between adrenergic autoantibodies and POTS. They support the concept that
allosteric-mediated shifts in the a1AR and b1AR responsiveness are important in the pathophysiology of postural
tachycardia.
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Introduction
Postural tachycardia syndrome (POTS) is a functional cardiovas-
cular disorder characterized by excessive heart rate increase and
discomfort during orthostasis, usually accompanied by a spectrum
of non-specific symptoms such as sporadic syncope, orthostatic
intolerance, deconditioning, headache, cognitive impairment, and
gastrointestinal dysfunction.1,2 The syndrome affects predominantly
young women (70–80%) within a range of 15–40 years, first being
defined in 1990s as a variant of orthostatic intolerance and dysauto-
nomic syncope, but its aetiology remains unknown.3 – 5 Postural
tachycardia syndrome is considered to be one of the most common
autonomic disorders, with an estimated prevalence of 0.5 million in
United States of America alone. Its onset may follow an acute
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infection or vaccination but more commonly appears without ante-
cedent causative events.2,6 It often leads to debilitating symptoms
and uncertain long-term prognosis.1 A number of treatment options
have been proposed in POTS but their efficacy in the more severe
forms is limited and often questioned.2,7 Since the pathophysiologic-
al basis for POTS is unclear, therapeutic interventions are empirical.
POTS-related syncope differs from classic vasovagal syncope
(VVS), as the underlying symptoms are present constantly with oc-
casional syncope associated with a preceding tachycardia and asso-
ciated adrenergic symptoms. In contrast, VVS typically features
episodic syncope and asymptomatic periods between attacks.1,4,7
Li et al. recently reported that activating autoantibodies (AAb) to
the a1-adrenergic (a1AR) and b1/2-adrenergic receptors (b1/2AR)
might play a pathophysiological role in POTS.8 In that pilot study,
the investigators used a limited number of POTS subjects (n ¼ 7)
and controls from their institution; and added 7 additional POTS sub-
jects and 4 controls submitted in a blinded fashion from an independ-
ent institution for a more rigorous confirmation of the discovery. This
first study used a functional assay based on immunoglobulin G
(IgG)-induced changes in a1AR and b2AR-mediated contractility of
small arterioles in vitro. While effective, this technique is tedious and
does not lend itself to screening larger number of patients. In the pre-
sent study, we planned to examine the AAb profile of a larger, well-
characterized, and representative cohort of patients with POTS
from an independent European institution whose selection was com-
pletely separate from the originating laboratory. We chose to include
two control groups, one being an autonomic control with patients
presenting with classic recurrent VVS and the other as normal healthy
volunteers without a history of syncope. The study was designed to
examine the effect of patient-derived IgG on the activation of adren-
ergic receptors in transfected cells as well as IgG impact on the adren-
ergic receptor responsiveness to the well-characterized orthosteric
ligands such as phenylephrine and isoproterenol.
Methods
Study patients
SYSTEMA (Syncope Study of Unselected Population in Malmo¨) is an on-
going single-centre project aiming at studying syncope epidemiology,
pathophysiology, and prognosis in the general population.9 Within the
SYSTEMA cohort, we randomly selected 17 patients with a confirmed
diagnosis, by clinical history and tilt testing, of POTS (16 females; age,
26+ 9 years), and 7 with recurrent VVS (5 females; age: 31+9 years).
These patients were investigated at the Syncope Unit of Ska˚ne Univer-
sity Hospital between February 2011 and March 2014. The POTS pa-
tients reported at least 3 months duration of characteristic symptoms
such as orthostatic intolerance, tiredness, headache, and were unre-
sponsive to conventional therapy with persistent symptoms of ortho-
static intolerance during blood collection. In contrast, VVS patients
were selected among those who reported recurrent syncope prior to
diagnosis, and were free from symptoms between the episodes of syn-
cope. Eleven normal controls (10 females; age, 31+6 years) were re-
cruited at the study site in Sweden among healthy individuals without
any history of syncope, autoimmune disease, and with a normal postural
haemodynamics during active standing (i.e. pulse increase,30 bpm and
absence of orthostatic hypotension).10,11 All the patients and controls
were recruited from the same community of Malmo¨ or neighbouring
municipalities in Ska˚ne Region, Southern Sweden.
Examination protocol
The head-up tilt (HUT) test for SYSTEMA patients was performed ac-
cording to the Italian protocol.12 The tilt table was raised at constant
speed to 708 in 18 s, and had the same lowering time. The patients’
haemodynamic parameters and electrocardiogram were monitored
using a non-invasive beat-to-beat measurement device (Nexfin, BMEYE,
Amsterdam, the Netherlands).13 Study participants were instructed to
fast for 2 h before the test, and they were allowed to drink water
ad libitum. Participants were also asked to complete a questionnaire,
referring to their past medical history, duration, frequency and charac-
teristics of syncope, smoking status, and current medication. The
Regional Ethical Review Board in Lund, Sweden approved the study
protocol (ref no 82/2008), and all study participants gave their written
informed consent including serum analyses.
Diagnostic criteria of postural tachycardia
syndrome and classic vasovagal syncope
The test was diagnostic when patients demonstrated a typical prodrome
(such as palpitation, nausea, dizziness, lightheadedness, or intense per-
spiration) reproducing previous events experienced and/or precipitated
syncope, and the haemodynamic parameters met the diagnostic criteria
of POTS or VVS, respectively.4,11,14 Briefly, POTS was defined as char-
acteristic symptoms of orthostatic intolerance (lightheadedness, dizzi-
ness, and/or discomfort) with a maximal and persistent heart rate
increase of .30/min (or ≥40/min for those aged ≤19 years) or tachy-
cardia of .120/min in standing position, and the absence of orthostatic
hypotension, i.e. max systolic/diastolic BP drop was ,20/10 mmHg on
head-up tilt.2,11 Vasovagal syncope was defined as a reproduction of
syncope during HUT associated with a characteristic pattern of pro-
nounced hypotension, bradycardia, or asystole.4 In order to ascertain
the accuracy of diagnoses, the digital test records were subsequently
inspected off-line using Nexfin@PC (BMEYE, Amsterdam, the Nether-
lands), dedicated software provided by the manufacturer.
Sample preparation
Blood samples for the present study were obtained post-test (i.e. after
the diagnostic HUT was performed) following overnight fasting. A
trained nurse performed an antecubital venipuncture in a dedicated
room after 10 min rest in supine position. Serum was separated by cen-
trifugation and stored at2808C prior to shipping of duplicate aliquots in
dry ice to the laboratory in Oklahoma City. The frozen integrity of each
What’s new?
† Serum from patients diagnosed with postural tachycardia
syndrome contains circulating autoantibodies with a direct
stimulatory effect on adrenergic receptors.
† The autoantibodies may also exert an allosterically mediated
positive modulatory effect upon b1AR and a negative modu-
latory effect on a1AR activity.
† These and possibly other yet-to-be identified immunoglobu-
lins with different target epitopes might explain different
constellations of symptoms in POTS.
† This concept, if validated, would provide concrete support
for novel therapeutic approaches against POTS based on
immunotherapy.
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aliquot was confirmed upon arrival and samples were immediately
placed in a 2808C freezer prior to thawing of one aliquot for the first
assay. Serum IgG was purified using the NAb Protein A/G Spin Kit
(Pierce Biotechnology). Receipt and assay of these de-identified samples
was approved by the University of Oklahoma Health Sciences Center
Institutional Review Board.
Cell-based a1AR assay
Immunoglobulin G activation of a1AR in a1AR-NFAT-bla CHO-K1
cells was assessed using the GeneBLAzer FRET-based b-lactamase re-
porter assay (Invitrogen) according to manufacturer’s instructions.
Briefly, cells were plated in 96-well plates and incubated overnight.
The individual IgG (0.1 mg/mL) samples and positive and negative con-
trols were then added and incubated for 5 h. The a1AR blocker prazo-
sin (10 mM) was used for specific blockade. The b-lactamase substrate
CCF4-AM (LiveBLAzer-FRET B/G Loading Kit, Invitrogen) was then
added and incubated for 2 h. The plates were read using a fluorescence
microplate reader (BioTek Synergy 2 Multi-Detection Microplate Read-
er). All samples were assayed in triplicate. Negative (buffer) and positive
(phenylephrine) controls were included in each assay. Data were
expressed as the ratio of the emissions 460/530 nm (blue/green) after
subtraction of the background values.
Full dose–response curves for phenylephrine (10210–1025 M) were
generated in three known positive POTS subjects in the absence and
presence of IgG (0.1 mg/mL) to examine the allosteric effect of IgG
on the a1AR orthosteric ligand phenylephrine. We then used a simpli-
fied one dosage (1026 M) phenylephrine response in the absence and
presence of IgG from the POTS subjects and the normal controls to
examine whether an apparent change in sensitivity existed irrespective
of whether a direct activation of the receptor by the IgG was present.
Cell-based b1/2AR assay
Immunoglobulin G-mediated b1AR and b2AR activation of cAMP pro-
duction in transfected CHO cells (with either b1AR or b2AR stimula-
tion) was measured using the cAMP Hunter eXpress GPCR Assay kit
(DiscoveRx) as described.8,15 Briefly, b1AR- or b2AR-CHO cells
were dispensed into 96-well plates and incubated overnight. The me-
dium was then removed and assay buffer containing the cAMP antibody
and serum-derived IgG (0.1 mg/mL) was added in the presence and ab-
sence of the non-selective bAR blocker propranolol (1 mM) and incu-
bated for 30 min. The cAMP standard, negative (buffer), and positive
(isoproterenol) controls were included in each assay. All samples
were tested in triplicate. Following sample treatment, cAMP detection
reagent and solution were added, and chemiluminescent signal was
read on a TD-20/20 Luminometer (Turner BioSystems). The cAMP va-
lues generated for each assay were expressed as relative luminescence
unit (RLU).
Dosage response curves for isoproterenol (10210 –1026 M) in
b1AR-CHO cells in the absence and presence of IgG (0.1 mg/mL)
from three positive POTS subjects were constructed to examine
the allosteric effect of IgG on the b1AR orthosteric ligand iso-
proterenol. Likewise, a simplified single dosage isoproterenol
(1026 M) response was examined using IgG from the POTS subjects
and the normal controls to determine if an allosteric-mediated effect
on the b1AR-CHO cells was present independent of any direct
activation from the IgG.
Isolated cremaster arteriole assay
The vasoconstrictor effect of IgG activation of a1AR on resistance ves-
sels was examined using an isolated rat cremaster arteriole assay as pre-
viously described.8 After equilibration in the presence of propranolol
(1 mM) and the nitric oxide synthase inhibitor L-NAME (1 mM) to elim-
inate any b2AR- and M3muscarinic receptor-mediated vasodilation and
to achieve steady-state myogenic tone, the arterioles were perfused
with IgG (0.05 mg/mL) and their effects on vessel diameter were re-
corded. Phentolamine (10 mM) was used to specifically block a1AR ac-
tivity. The buffer baseline diameters were normalized to 100% and
subsequent IgG-induced contractility was reported as percentage of
baseline. This procedure was approved by the Oklahoma University
Health Sciences Center Institutional Animal Care and Use Committee.
Statistical analyses
Data are expressed as mean+ SD. Group comparisons were per-
formed using Student’s t-test for comparison of two groups, or one-way
ANOVA followed by post hoc Tukey’s test for multiple group compari-
son. Pearson’s x2-analysis was used to compare categorical variables.
The positivity of bioactive autoantibodies was defined as values above
the mean + 2SD or below the mean 2 2SD from the control group.
A linear regression analysis was performed to examine the relationship
between the haemodynamic parameters resting supine plus during
head-up tilt and direct IgG-mediated receptor bioactivity. Analyses
were performed using IBM SPSS Statistics version 22 (SPSS Inc.,
Chicago, IL, USA). Statistical significance was set at P, 0.05.
Results
Clinical characteristics
The demographic and clinical characteristics for each group are
shown in Table 1. The mean age for the POTS patients was not sig-
nificantly different from those with VVS and control subjects. All pa-
tients in the POTS group had documented persistent increase in
heart rate .30 bpm vs. supine during head-up-tilt with reproduc-
tion of typical orthostatic intolerance symptoms. There was no sig-
nificant difference in BP response during the first 3 min of head-up
tilt in the POTS compared with VVS and controls and there was no
significant difference in catecholamine profile supine and 3-min
HUT between POTS and VVS (see Supplementary material online,
Table S1). The VVS group reported a longer history of syncopal
symptoms (P ¼ 0.017), but the number of syncope episodes, pro-
portions of characteristic precipitating symptoms, and self-reported
dizziness on standing did not differ between POTS and VVS patients.
Autoantibody activity
The activities of autoantibodies against the a1AR and b1/2AR were
examined using IgG (0.1 mg/mL) in cell-based bioassays. These data
are shown in Figure 1. Among the 17 patients with POTS, 8, 11, and
12 showed direct activation of a1AR (47%), b1AR (65%), and b2AR
(71%), respectively (Figure 1A–C). Based on these direct assays, 6 of
these 17 POTS patients (35%) harboured both a1AR- and
b1AR-AAb (Table 2). None of these autoantibodies were found
in the patients with VVS or healthy controls. Themean activity values
of a1AR, b1AR and b2AR autoantibodies were all significantly higher
in the POTS group than for both VVS and normal controls (a1AR:
POTS 0.31+ 0.07(SD) vs. VVS 0.24+ 0.04 and control 0.23+
0.04, P ¼ 0.029 and 0.004, respectively; b1AR: POTS 1840+ 186
vs. VVS 1578+117 and control 1608+127, P ¼ 0.002 and 0.001,
respectively; b2AR: POTS 1104+ 230 vs. VVS 816+ 73 and
control 837+72, P ¼ 0.007 and 0.001, respectively) (Figure 1A–C).
There was no significant difference between the latter two groups.
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The mean activities of a1AR, b1AR, and b2AR autoantibodies in 13
POTS patients were markedly suppressed by the a1AR blocker pra-
zosin (10 mM, from 0.52+ 0.06 to 0.46+ 0.05, P ¼ 0.0001) and
b-blocker propranolol (1 mM, b1AR: from 1068+ 233 to 821+
71, P ¼ 0.0013; b2AR: from 1221+164 to 988+37, P ¼ 0.0001)
(Figure 1D–F). No significant effect of these blockers was observed
in the control group.
To examine the effect of autoantibodies on orthosteric ligand ac-
tivation of a1AR and b1AR, dosage response curves for phenyleph-
rine (10210-1025 M) and isoproterenol (10210–1026 M) with and
without POTS IgG (0.1 mg/mL) were constructed and compared.
Immunoglobulin G from three POTS patients who were positive
for a1AR and b1AR autoantibodies were used for curve compari-
sons. In the presence of POTS IgG, the phenylephrine response
curve was shifted to the right, demonstrating a decreased a1AR re-
sponse (Figure 2A). In contrast, the isoproterenol response curve
was significantly shifted to the left, demonstrating an enhanced
b1AR response with b1AR autoantibodies (Figure 2B). Neither
shift was observed using control IgG. We then tested the effect
of IgG (0.1 mg/mL) from all 17 POTS subjects on the responses
to phenylephrine (1 mM) and isoproterenol (1 mM). There was a
significant decrease in phenylephrine-induced a1AR activation
with POTS IgG (0.13+ 0.02) compared with phenylephrine alone
(0.18+ 0.03, P, 0.0036) or IgG from normal controls (0.17+
0.02, P , 0.0005) (Figure 2C). The isoproterenol-stimulated
b1AR activation, on the other hand, was significantly increased
with POTS IgG (1835+ 309) compared with isoproterenol alone
(1479+ 86, P, 0.037) or IgG from normal controls (1508+ 80,
P, 0.032) (Figure 2D). Control IgG showed minimal modulating
effects.
When each individual data was plotted, 8 of the 17 POTS patients
demonstrated an inhibitory effect on phenylephrine-induced a1AR
activation using a cut-off value of the mean—2SD from the control
group (Figure 2E). Thirteen of the 17 POTS patients were positive
for an enhanced effect on isoproterenol-induced b1AR activation
using a cut-off value of the mean + 2D from the control group
(Figure 2F). There was some overlap for the a1AR and considerable
overlap for the b1AR with the other tests (Table 2). Overall, all
POTS subjects had at least one positive test.
Immunoglobulin G (0.05 mg/mL) from each subject with POTS
and 8 controls were tested for a1AR autoantibody-mediated con-
tractile activity using an isolated rat cremaster arteriole assay. A total
of 13 among the 17 POTS patients demonstrated significantly in-
creased contractility (Figure 3A). There was a significant difference
in the mean contractile activity between the POTS group and con-
trol group (91.0+ 3.1% vs. 96.5+1.3%, P, 0.0001). The control
subjects failed to produce any significant vasoactivity. Six POTS sub-
jects with positive a1AR autoantibodies and 6 controls were then
selected to test the effect of specific a1AR blockade. As shown in
Figure 3B, POTS IgG-induced contractility was largely returned to
baseline level by addition of the a1AR blocker phentolamine
(10 mM, from 88.9+ 3.0% to 96.5+2.1%, P ¼ 0.0006). Phentola-
mine had no significant impact on control IgG activity.
In the linear regression analysis, IgG-mediated b1AR activity was
strongly correlated with both 3 min (P ¼ 0.0009) and maximal up-
right heart rate (P ¼ 0.0006), whereas the latter was also correlated
with a1AR activity (P ¼ 0.039) but not with b2AR activity (P ¼
0.11). Neither SBP nor DBP were correlated with adrenergic recep-
tor stimulation.
Discussion
We have demonstrated that serum from subjects with POTS con-
tains circulating autoantibodies, some with a direct stimulatory
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Characteristics of patients with POTS, VVS and controls
POTS
(n 5 17)
VVS
(n5 7)
Controls
(n5 11)
P-valuea VVS/
Controls vs. POTS
Age 25+7 31+9 31+6 0.17/0.063
Sex M/F 2/15 2/5 1/10 0.55/0.98
Systolic BP supine 121+14 123+6 112+8 0.95/0.92
Diastolic BP supine 71+8 71+3 70+9 1.0/0.97
Heart rate supine 73+10 73+8 70+9 1.0/0.63
Systolic BP upright 3 min 122+14 125+6 112+8 0.78/0.069
Diastolic BP upright 3 min 80+8 78+5 77+10 0.84/0.63
Heart rate upright 3 min 100+14 82+10 78+9 0.004/0.0002
Heart rate max upright 111+13 90+10 – 0.001
Duration of symptoms (years, median, interquartile range) 3 (1–6) 10 (2–24) – 0.017
No. of syncope (median, interquartile range) 4 (1–30) 10 (3–10) – 0.67
Autonomic symptoms (nausea, perspiration) preceding
syncope (n, %)
8 (47) 5 (71) – 0.34
Palpitations preceding syncope (n, %) 4 (24) 3 (43) – 0.39
Orthostatic dizziness (n, %) 13 (77) 4 (57) – 0.23
BP, blood pressure.
aOne-way ANOVA plus Tukey post hoc adjustment (for continuous variables) and Pearson’s x2 test (for categorical variables) were applied.
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effect on adrenergic receptors. A majority also exerted an allosteri-
cally mediated positive modulatory effect upon b1AR and a negative
modulatory effect on a1AR activity. These and possibly other
yet-to-be identified immunoglobulins with different target epitopes
may exert varying biological effects in particular patients, which may
explain different constellations of symptoms in POTS. It is of interest
that IgG-mediated b1AR and a1AR activation were correlated with
the heart rate increase on standing. The relatively high correlation
with the b1AR autoantibody activity would appear to be clinically
relevant. The lower but still significant relationship of the allosteri-
cally mediated inhibitory action of the a1AR response would
secondarily lead to the increase in heart rate by reflexly increasing
circulating catecholamines.
The primary objective of this study was to determine if autoanti-
bodies with the capacity to modify the activity of autonomic adren-
ergic receptors, previously reported in POTS patients in the USA,8
were likewise present in a cohort of POTS subjects from a European
location. A secondary goal included usage of an ‘autonomic’ control
group characterized by subjects with recurrent VVS. This permitted
us to determine if such autoantibodies were different between nor-
mal subjects and POTS; and as well between POTS and a group with
recurrent VVS. These latter two groups shared somewhat broadly
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Figure 1 Effects of serum IgG (0.1 mg/mL) from POTS and VVS patients and healthy control subjects on direct activation of a1AR, b1AR, and
b2AR in cell-based bioassays. The a1AR activity is expressed as the FRET blue/green response ratio, and the b1/2AR activity is expressed as RLU.
There was a significant increase in a1AR (A), b1AR (B), and b2AR (C) activity in the POTS group compared with the VVS and control groups. The
addition of the a1 blocker prazosin (10 mM) or non-selective b-blocker propranolol (1 mM), respectively, suppressed the a1AR (D), b1AR (E),
and b2AR (F ) activity values to control levels. The dashed line is the threshold derived from the mean activity values + 2SD of the healthy
controls.
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based autonomic disorders but clearly were different from each
other and from normal controls. A third goal was to develop bio-
activity assays that might permit larger scale testing for pathophysio-
logical and therapeutic study.
For the primary objective, we found that antiadrenergic a1AR
autoantibody activity was evident in POTS, while the VVS subjects
were not different from normal subjects. In contrast to our initial
publication,8 nearly half of the POTS subjects had direct activation
of the a1AR autoantibody activity. The a1AR activity in our previ-
ous study was assayed using IgG in an arteriolar assay and not the
present cell-based assay. For this reason, we re-assayed IgG from
each POTS patient and a representative group of the controls in
the rat cremaster arteriole assay. These data showed a heteroge-
neous response in which the majority with increased a1AR activity
from the cell-based assay also demonstrated arteriolar contractile
activity. Eight subjects with no a1AR direct activity from the cell-
based assay also demonstrated positive contractile activity, while
three subjects with positive a1AR activity from the cell-based assay
demonstrated no arteriolar contractile activity.
We then examined the impact of representative IgG from POTS
and normal controls on phenylephrine dosage response curves. As
previously reported,8 these data confirmed the active a1AR auto-
antibodies inhibited the phenylephrine response and shifted the
phenylephrine dosage response curve to the right. These autoanti-
bodies appear to function as partial agonists and the absence of
measurable direct activation of the transfected receptors in vitro in
the absence of their normal ligand does not exclude their presence.
It is possible this allosteric impact on the activity of the a1AR ligand
norepinephrine represents the distinct pathophysiological feature
characteristic of POTS. Consequently, identification of the antiadre-
nergic autoantibodies may additionally require testing for altered
dosage response curves using established receptor orthosteric
agonists.
b1/2AR autoantibody activity was increased in POTS but not in
VVS. In the present study, approximately two-thirds activated
b1/2AR in cell-based assays. Moreover, b1AR autoantibodies
enhanced the isoproterenol response and most importantly shifted
the isoproterenol dosage response curves to the left, confirming
our previous observations.8
Postural tachycardia syndrome continues to be a vexing dysauto-
nomia2 that has long challenged afflicted patients, their families, and
caregivers. The variable presentation and seemingly associated
autonomic disorders, and other non-specific symptoms including
gastroparesis, migraine headaches, chest pain, chronic fatigue, and
mental confusion (brain-fog) have perplexed medical personnel.
Thus, it is important to define the aetiology and develop a rationale
for specific interventions for controlling the underlying pathophysi-
ology and thereby providing symptomatic relief. There has long
been speculation that the predilection for POTS in younger females
and occasional association with a viral/bacterial infection, vaccin-
ation or a stress event would support an autoimmune component
in its aetiology.6,16,17
Recognition that circulating autoantibodies interact with G
protein-coupled receptor targets and modify the autonomic system
has led our group to identify AAb to the b2AR and M3 muscarinic
acetylcholine receptor in a group of subjects with idiopathic ortho-
static hypotension.15 The present study focused on the activity ex-
pected with these receptors; but identified a unique property of
the studied IgG directed toward the a1AR which exerted allosteric
effects characteristic of a partial agonist since its presence shifted
the phenylephrine dosage response curve to the right. In contrast,
the b1AR effect was just the opposite and shifted the b1AR agonist
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Test positivity (direct-activating and/or ligand-modulating activity) among patients diagnosed with POTS
Patient no. a1AR Ab b1AR Ab b2AR Ab
Activating Modulating Activating Modulating Activating
1 x x
2 x x
3 x x x x
4 x x x x
5 x x x
6 x x x
7 x x x
8 x x x
9 x x
10 x x x
11 x x x
12 x x x x x
13 x x
14 x x
15 x x
16 x x x x
17 x x x x x
Total 8/17 8/17 11/17 13/17 12/17
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dosage response curve to the left. It is likely that under these con-
ditions, the primary action of the autoantibodies is not an orthos-
teric direct activation or inhibition of the receptor but rather
modulation of the activity and action of the ligand norepinephrine/
epinephrine that normally is involved in the particular receptor
transduction. These contrasting effects provide an appealing explan-
ation for the cardiovascular effects associated with upright posture
in those so afflicted.1,8
We believe that the present study helps affirm our concept that
common cardiovascular dysautonomias may express a spectrum of
autoantibodies, which contribute to a variety of clinical manifesta-
tions. This spectrum would certainly range from subclinical to overt
expressions that may overlap with other entities such as inappropri-
ate sinus tachycardia (IST), where circulating antibodies against car-
diac b-receptors have been previously reported.18 Both POTS and
IST share abnormal sinus tachycardia tendency, and differ in regard
to resting heart rate control that is usually preserved in POTS but
not in IST.2 Thus, some subjects who do not formally meet the diag-
nostic criteria of POTS may have partial presentation of such auto-
antibodies. From our studies, subjects with recurrent VVS and
normal orthostatic tolerance would not be likely candidates for in-
clusion in this grouping. We have recently demonstrated an exag-
gerated catecholamine response in postural tachycardia among
patients with syncope and dysautonomic cardiovascular response
to orthostasis.19 The catecholamine surge may be seen as a com-
pensatory mechanism to override the a1AR malfunction associated
with the proposed autoimmune blockade as present in POTS pa-
tients but this explanation is unlikely in those with recurrent VVS.
Although it is likely that POTS has multiple causes, there has been
a paucity of concrete evidence for other pathophysiological bases
for an underlying pathophysiology to date for the vast majority of
patients. It seems apparent that the high percentage of POTS sub-
jects examined by our group present with an apparent autoimmune
diathesis that supports the concept that these autoantibodies play
important role in the pathophysiology of this entity.
Strengths and limitations
This report more than doubles the number of our previous obser-
vations, and focuses on a tightly characterized group of patients and
controls. We have introduced a new direct assay to measure a1AR
activity, which although similar in principle to the assay for b1/2AR
in transfected cells was only positive in half of the POTS patients
compared with the more demanding previous bioassay that mea-
sured contractility in the cremaster arterioles in vitro. This cremaster
arteriolar bioassay is not suitable for use in large numbers of samples
and the specific cell-based assays are an improvement with regard to
numbers. Diagnostic criteria based on measuring the autoanti-
bodies’ impact on an allosteric-mediated receptor response to the
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Figure 2 Effects of IgG (0.1 mg/mL) from POTS patients on PE and ISO responses in cell-based assays. IgG from 3 POTS patients with
a1AR-activating activity shifted the PE dosage response curve to the right indicating an inhibitory allosteric effect (A). In contrast, IgG from 3
b1AR antibody-positive POTS patients shifted the ISO dosage response curve to the left compatible with a positive allosteric effect. Control
IgG failed to alter these curves. When IgG from all 17 POTS patients was tested in the presence of PE (1 mM) or isoproterenol (1 mM), there
was a significant decrease in the PE response compared with PE alone and control IgG (C) and a significant increase in the ISO response compared
with ISO alone and control IgG (D). Control IgG showed minimal modulating effects. Individual data from (C) and (D) for the POTS and control
subjects are shown in (E) and (F), respectively. The dashed line is the threshold derived from the control mean values—2SD for the a1AR-
modulating effect or control mean values + 2SD for the b1AR-modulating effect.
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natural ligand may provide a more favourable estimate of autoanti-
body involvement in the complex pathophysiology of POTS. This
study has an important limitation as the parasympathetic tonus
was not assessed during HUT, and possible autoantibodies against
muscarinic receptors and/or acetylcholine system were not investi-
gated. The vagal drive may have an important implication in related
POTS symptomatology.20 Finally, the study groups were not strictly
age matched, although the age difference was not significant.
Conclusion
The marked presence of either or both a1AR and b1/2AR auto-
antibodies with their potent allosteric impact on the relevant
orthosteric ligands provides an appealing framework to support
an autoimmune pathophysiology of POTS. This concept, if validated,
would provide concrete support for novel therapeutic approaches
against POTS based on immunotherapy. These could currently in-
clude suppression of autoantibody production using immunoglobu-
lin infusions and in the foreseeable future by development of decoy
peptides that are specific for autoantibodies that target the identi-
fied receptor epitopes.
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reversed POTS IgG-mediated contractility to control levels (B).
There was no significant change in contractile activity with phen-
tolamine for the control IgG.
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